Mikhael Joseph, Bhutani Manisha, Cole Craig E
Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, Ariz; International Myeloma Foundation, Studio City, Calif.
Department of Hematologic Oncology and Blood Disorders, Division of Plasma Cell Disorders, Atrium Health/Wake Forest Baptist, Levine Cancer Institute, Charlotte, NC.
Am J Med. 2023 Jan;136(1):33-41. doi: 10.1016/j.amjmed.2022.08.030. Epub 2022 Sep 20.
Multiple myeloma is the second most common hematologic malignancy in the United States and the most common hematologic malignancy among Blacks/African Americans. Delay in diagnosis is common and has been associated with inferior disease-free survival and increased rates of myeloma-related complications. Despite a roughly 2-times higher risk of multiple myeloma, diagnostic delay appears more common, and improvements in 5-year survival rates have been slower among Blacks/African Americans than their White counterparts. When patient symptoms and basic laboratory findings are suggestive of multiple myeloma, the primary care provider should initiate extended laboratory work-up that includes serum protein electrophoresis, serum immunoglobulin free light chain assay, and serum immunofixation. Heightened awareness within high-risk populations such as Blacks/African Americans may help to eliminate racial disparities in the diagnosis and treatment of multiple myeloma.
多发性骨髓瘤是美国第二常见的血液系统恶性肿瘤,也是黑人/非裔美国人中最常见的血液系统恶性肿瘤。诊断延迟很常见,且与无病生存期较差以及骨髓瘤相关并发症发生率增加有关。尽管黑人/非裔美国人患多发性骨髓瘤的风险大约高出2倍,但诊断延迟似乎更为常见,而且黑人/非裔美国人的5年生存率改善速度比白人慢。当患者症状和基本实验室检查结果提示多发性骨髓瘤时,初级保健提供者应启动包括血清蛋白电泳、血清游离轻链免疫球蛋白测定和血清免疫固定在内的扩展实验室检查。提高对黑人/非裔美国人等高风险人群的认识可能有助于消除多发性骨髓瘤诊断和治疗中的种族差异。